Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sparsentan
- Development stage
- Approved
- Lead developer
- Travere Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sparsentan is a first-in-class, orally active small molecule that acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). It is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. By blocking both ETAR and AT1R, sparsentan inhibits two key pathways involved in kidney disease progression—endothelin-1 and angiotensin II signaling—resulting in anti-inflammatory, antifibrotic, and hemodynamic protective effects on the kidney. Sparsentan was developed by merging structural elements from irbesartan (AT1R antagonist) and biphenylsulfonamide (ETAR antagonist). The drug is approved under accelerated approval based on its ability to reduce proteinuria[1][2][6][8].
- Brand names
- Filspari
- Other names
- sparsentan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on sparsentan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sparsentan.